• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersThe Capsule

Who are the best health care leaders under 40?

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
June 25, 2020, 7:47 PM ET

Good evening, readers.

Some news for you. In July, The Capsule will be going out more regularly to all of our readers. You’ll be receiving the latest news about digital health, drug development, and the business and policy of public health daily.

We’d love to know if you have any ideas for what we should focus on in our coverage. The coronavirus pandemic has obviously (and for good reason) taken up a lot of space in medical reporting.

But COVID is far from the only issue that needs addressing in U.S. Health care. Gene therapies for blood disorders have hit milestones; cancer therapies continue to evolve. None of the public health problems we faced before this bizarre moment have magically disappeared any more than the reality of heart disease or so many other scourges.

And to that spirit of crowd sourcing… Coins2Day is looking for submissions for our 40 Under 40 list. I urge you to send any suggestions of stars in healthcare my way.

See you again next week (on a more regular basis). Read on for the day’s news.

Sy Mukherjee
[email protected]
@the_sy_guy

DIGITAL HEALTH

FDA clears Medtronic's brain stimulation impant. The Food and Drug Administration (FDA) has cleared another product from medical device specialist Medtronic: a deep brain stimulation implant meant to help create more personalized treatments for neurological diseases such as Parkinson's disease and epilepsy. It's linked to a mobile device created by Samsung. "For the first time, this technology gives clinicians feedback directly from the DBS patient’s brain," said Mike Daly of Medtronic. "With such data-driven, patient-specific insights, we believe it can change the standard of care." (FierceBiotech)

INDICATIONS

The NIH is intimately tied to Moderna's experimental COVID vaccine. The National Institutes of Health (NIH) has a deeper stake in upstart biotech Moderna's experimental coronavirus vaccine, according to Axios. In fact, having a stake at all could have wide-ranging implications for the treatment since the government could influence its eventual pricing. Moderna's vaccine would be, if cleared by the FDA, the company's first approved or authorized product and uses a unique but as-of-yet largely unproven biological technology. (Axios)

THE BIG PICTURE

Elective surgeries suspended in Texas as coronavirus cases skyrocket. As COVID cases and related hospitalizations skyrocket in Texas, governor Greg Abbott has issued an executive order barring elective surgeries in several of the state's largest metropolitan areas. “These four counties have experienced significant increases in people being hospitalized due to COVID-19, and today’s action is a precautionary step to help ensure that the hospitals in these counties continue to have ample supply of available beds to treat COVID-19 patients,” wrote Abbott in his statement. There were more than 4,400 hospitalized COVID patients in Texas as of Wednesday, and some adult patients have had to be funneled to the Texas Children's Hospital due to the diminished capacity. (Coins2Day)

REQUIRED READING

Coronavirus CEO pay cuts were short-lived, by Emma Hinchliffe

Coming out of a crisis the boldest companies win, by Geoff Colvin

Why America won't be going cashless anytime soon, by McKenna Moore

Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.